Interference between anti-HLA antibodies and adrenergic receptor-binding drugs.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000906:Antibodies; D001058:Apomorphine / Q000494:pharmacology; D001666:Binding Sites, Antibody / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D003429:Cross Reactions; D004298:Dopamine / Q000494:pharmacology; D000939:Epitopes; D005260:Female; D006680:HLA Antigens; D006220:Haloperidol / Q000494:pharmacology; D006649:Histocompatibility Antigens; D006801:Humans; D007106:Immune Sera; D008214:Lymphocytes / Q000276:immunology; D011433:Propranolol / Q000494:pharmacology; D013469:Sulpiride / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000906:Antibodies; D000939:Epitopes; D006680:HLA Antigens; D006649:Histocompatibility Antigens; D007106:Immune Sera; D013469:Sulpiride; D011433:Propranolol; D006220:Haloperidol; D001058:Apomorphine; D002746:Chlorpromazine; D004298:Dopamine